1. Introduction {#sec1-jcm-07-00381}
===============

Pneumonia, a leading cause of mortality, places a heavy burden on both communities and healthcare systems \[[@B1-jcm-07-00381],[@B2-jcm-07-00381]\]. Tuberculosis (TB) is a prevalent nosocomial infection, which often results in disability \[[@B3-jcm-07-00381]\]. Chronic airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are associated with pneumonia \[[@B4-jcm-07-00381],[@B5-jcm-07-00381]\].

Hyperlipidemia was found to be a predisposing factor for pneumonia in one study \[[@B6-jcm-07-00381]\] but was reported to be a factor potentially preventing TB in another study \[[@B7-jcm-07-00381]\]. Cholesterol in the foamy macrophage plays a critical role in the reactivation of latent TB and the mentation of a persistent chronic TB infection. Phagosomal maturation and autophagy are responsible for the elimination of the bacteria and TB bacilli. A statin-mediated reduction in cholesterol levels within the phagosomal membranes potentially counteract the TB-induced inhibition of phagosomal maturation and promote host-induced autophagy, thereby augmenting protection against TB \[[@B8-jcm-07-00381]\]. The role of cholesterol in pneumonia and TB development has been widely debated \[[@B9-jcm-07-00381]\].

Statins exert anti-inflammatory effects on system inflammation and airway diseases such as asthma and COPD \[[@B10-jcm-07-00381],[@B11-jcm-07-00381],[@B12-jcm-07-00381]\]. Pneumonia may increase an individual's chances of contracting asthma and COPD later in life. Moreover, this condition is particularly responsible for the acute exacerbation of these two diseases. Fewer statin-using chronic respiratory disease patients \[[@B13-jcm-07-00381]\] developed pneumonia than those not using statin \[[@B14-jcm-07-00381]\]. Because bacteria attach to cell surfaces, cholesterol may be vital for the uptake and internal transport of certain bacteria \[[@B15-jcm-07-00381]\]. Statins attenuate cholesterol levels, resulting in a lower chance of bacteria entering the cell to reproduce and destroy lung tissue. Moreover, cholesterol-lowering statins boost bacteria-killing cells \[[@B16-jcm-07-00381]\]. By using human airway epithelial cells as an in vitro model, Statt et al. reported that prior exposure to physiological nanomolar serum concentrations of simvastatin (range 10--1000 nM) confers a significant cellular resistance to the cytotoxicity of pneumolysin, a pore-forming toxin that is the main virulence factor of *Streptococcus pneumonia* \[[@B17-jcm-07-00381]\]. Therefore, hyperlipidemia with statin use may reduce the risk of pneumonia \[[@B18-jcm-07-00381]\].

Asthma--chronic pulmonary disease overlap syndrome (ACOS) has components of both asthma and COPD. ACOS patients may have higher pneumonia \[[@B19-jcm-07-00381]\] and TB \[[@B20-jcm-07-00381]\] risks in the later course than do COPD patients \[[@B21-jcm-07-00381]\]. Statins have anti-inflammatory and immunomodulatory properties, potentially resulting in reduced reactivation of latent TB; statins modulate T cell count and cytokine levels during pneumonia \[[@B22-jcm-07-00381],[@B23-jcm-07-00381]\]. Few studies have reported on the relationship of statin, inhaled corticosteroid (ICS), or oral steroid (OS) use with TB or pneumonia in ACOS patients \[[@B24-jcm-07-00381],[@B25-jcm-07-00381]\]. We explored this relationship in reference to the general population \[[@B26-jcm-07-00381]\].

2. Methods {#sec2-jcm-07-00381}
==========

2.1. Data Source {#sec2dot1-jcm-07-00381}
----------------

This retrospective cohort study was conducted using data from the Longitudinal Health Insurance Database of one million enrollees extracted from the Taiwan National Health Insurance (NHI) Research Database (NHIRD) between 2000 and 2011 \[[@B27-jcm-07-00381]\]. The NHI program, implemented since 1995, provides comprehensive medical care to nearly all of Taiwan's population and covers the registry of beneficiaries, ambulatory care, inpatient care, prescriptions, and other medical services. This program has been described in numerous studies; for instance, by using 2005--2009 data from the NHIRD \[[@B28-jcm-07-00381]\], Cheng et al. reported no association between cumulative statin use and intracranial hemorrhage risk in patients without a past history of stroke. This experience was incorporated into the 2017 Taiwan lipid guidelines for high risk patients \[[@B29-jcm-07-00381]\]. Similarly, our study can provide baseline trends useful for further research on statins or other hyperlipidemia drug use \[[@B30-jcm-07-00381]\]. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used to define the diseases. This research was approved by the Research Ethics Committee at China Medical University and Hospital, Taiwan (27 June 2018, CMUH104-REC2-115-CR3).

2.2. Patients {#sec2dot2-jcm-07-00381}
-------------

The patients aged ≥18 years diagnosed as having ACOS \[i.e., COPD (ICD-9-CM codes 491, 492, and 496) and/or asthma (ICD-9-CM code 493)\] between 2000 and 2010 were selected. The date of ACOS diagnosis was defined as the index date \[[@B26-jcm-07-00381],[@B31-jcm-07-00381]\]. Patients aged \<18 years or having baseline diagnoses of TB (ICD-9-CM codes 010--018) or pneumonia (ICD-9-CM codes 481--486) were excluded. Patients who did and did not receive statin treatment were defined as statin users and nonusers, respectively.

2.3. ACOS, Pneumonia, and TB Patient Validation {#sec2dot3-jcm-07-00381}
-----------------------------------------------

In Taiwan, COPD is diagnosed through chest X-ray (CXR; 84.7%), computed tomography (CT; 39.4%), pulmonary function test (PFT; 58.44%), and smoking status (82.9%) \[[@B32-jcm-07-00381]\]. Su et al. report high sensitivity of these asthma (92.0%) and COPD (86.2%) \[[@B33-jcm-07-00381]\] diagnosis methods. ACOS patients undergo these diagnostic procedures often because medical services for diseases, such as pneumonia and TB, are easily available \[[@B21-jcm-07-00381],[@B23-jcm-07-00381]\]. Moreover, in the 12 months following the index date, ACOS patients undergo CXR, CT, and PFT more often than do COPD or asthma patients---which supports our speculations \[[@B26-jcm-07-00381]\]. Thus, extracting data of ACOS patients from among COPD and asthma patients in the NHIRD is reasonable.

We validated ACOS patients based on the following information: (1) Clinical manifestation in form of clinical symptoms or signs, such as chronic productive cough for 3 months in 2 successive years in a patient, wheezing, and dyspnea, aid early ACOS detection \[[@B34-jcm-07-00381]\]; (2) Imaging, particularly CXR, has a 90% sensitivity and 98% specificity for emphysema \[[@B35-jcm-07-00381]\] (51.0% of ACOS patients undergo CXR \[[@B26-jcm-07-00381]\]); (3) ICS or OS use is a useful tool for confirming ACOS patients \[[@B36-jcm-07-00381]\]. We used the anatomical therapeutic chemical code R03 for confirming of ACOS (24.0% and 76.0% ICS and OS use, respectively). Similarly, Su et al. reported ICS use in 53.48% of ACOS patients during follow-up \[[@B33-jcm-07-00381]\], and Shantakumar et al. reported ICS and OS use in 46.1% and 85.5% of ACOS patients during a 1-year follow-up \[[@B26-jcm-07-00381]\]. In the current study, 11,129 (98.9%) of 11,256 ACOS patients undertook COPD-, asthma-, TB-, or pneumonia-related diagnostic tests, such as CXR, PFT, CT, or immunoglobulin E levels, validating our ACOS cohort from the NHIRD.

In Taiwan, TB is confirmed through sputum culture and smear, CXR with clinical symptoms and signs, and therapeutic response to anti-TB drugs \[[@B37-jcm-07-00381]\]. Su et al. found that among 433 patients diagnosed as having TB, 326 received at least two anti-TB drugs for 4 weeks and were selected for validation of the TB definition. Of these, 314 were confirmed as having TB \[[@B38-jcm-07-00381]\] at a sensitivity of 96.3%. Pneumonia was confirmed through sputum smear and culture, blood culture, elevation in serum blood titer or urinary antigen levels, CXR, and therapeutic response to antibiotics \[[@B39-jcm-07-00381]\]. Overall, 284 of 300 inpatients and 277 of 300 outpatients were validated as having pneumonia, with a sensitivity was 94.7% and 92.3%, respectively.

Therefore, the TB and pneumonia codes in the NHIRD are typical reflect the real-world diagnosis of TB and pneumonia in Taiwan.

2.4. Outcome Measurement and Potential Comorbidities {#sec2dot4-jcm-07-00381}
----------------------------------------------------

The endpoint of this study was TB and pneumonia incidence. All study participants were followed up from the index date until death, withdrawal from insurance, or the study endpoint (31 December 2011). We also included potential TB- or pneumonia-related comorbidities, including sleep disorders, diabetes, hypertension, hyperlipidemia, mental disorders, alcohol-related illnesses, and chronic kidney disease. Other medications such as ICSs and OSs were included if they were potentially correlated with TB or pneumonia development.

2.5. Propensity Score Matching {#sec2dot5-jcm-07-00381}
------------------------------

Statin users and nonusers were matched at a 1:1 ratio based on their propensity scores. We used logistic regression to calculate the propensity score for each patient by estimating assignment probability according to the baseline variables of age, sex, comorbidities (sleep disorders, diabetes, hypertension, hyperlipidemia, mental disorders, alcohol-related illness, and chronic kidney disease), and use of other medications (ICSs and OSs). This ensured that a similar number of patients were included in both the cohorts with an equal probability to statin use.

2.6. Statistical Analysis {#sec2dot6-jcm-07-00381}
-------------------------

Differences in demographic distributions, baseline comorbidities, and medications between statin users and nonusers were compared using the chi-square test for categorical variables and Student's *t* test for mean ages. The Kaplan--Meier method was used to measure the cumulative TB or pneumonia incidence among statin users and nonusers. The cumulative curves of the two cohorts were tested using the log-rank test. However, ACOS patients may have taken their prescription irregularly during the study period; this may have led to an overestimation of the drug effects. To reduce this bias, we used Cox proportional hazard models with time-dependent exposure covariates \[[@B40-jcm-07-00381]\] to estimate the hazard ratios (HRs) and their 95% confidence intervals (CIs) for TB and pneumonia in statin users relative to nonusers. Next, aHRs were measured after adjustments for age, sex, comorbidities, and use of medications and stratification by age, sex, and ICS and OS use. Moreover, we performed sensitivity analysis by developing Cox models based on propensity score--matched cohorts to refine our results. All statistical analyses were performed using SAS (version 9.4 for Windows; SAS Institute, Inc., Cary, NC, USA). A two-tailed *p* of \<0.05 was considered statistically significant.

3. Results {#sec3-jcm-07-00381}
==========

[Table 1](#jcm-07-00381-t001){ref-type="table"} demonstrates that compared with nonusers, statin users were slightly younger (62.7 ± 11.7 vs. 64.4 ± 14.8 years), with a higher female: male ratio, higher prevalence of comorbidities, and higher likelihood of ICS or OS use.

The follow-up period was longer in statin users (8.18 ± 2.76 years) than in nonusers (5.99 ± 3.88 years; [Table 2](#jcm-07-00381-t002){ref-type="table"}). By the end of the 12-year follow-up, cumulative TB and pneumonia incidence was 3.39% and 5.3% lower in statin users than in nonusers, respectively (both *p* \< 0.001, log-rank test; [Figure 1](#jcm-07-00381-f001){ref-type="fig"}A,B respectively). Moreover, the time-dependent regression analysis after adjustment for age, sex, urbanization level, monthly income, occupation, comorbidities, and other medication use revealed that statin users had aHRs (95% CIs) of 0.49 (0.34--0.70) and 0.52 (0.41--0.65) for TB and pneumonia, respectively. TB and pneumonia incidence was respectively 2.21 and 5.23 per 1000 person-years in statin users and 6.96 and 13.7 per 1000 person-years in statin nonusers.

[Table 3](#jcm-07-00381-t003){ref-type="table"} lists TB and pneumonia incidence and HRs stratified by age and sex in both cohorts. Both male and female statin users had lower TB and pneumonia risks than did nonusers. Among patients aged ≥50 years, the TB and pneumonia risks were lower in statin users than in nonusers.

[Table 4](#jcm-07-00381-t004){ref-type="table"} presents TB and pneumonia incidence and HRs stratified by ICS and OS use in both cohorts. Compared with nonusers, statin use combined with ICS or OS use was significantly associated with lower pneumonia risk in statin users; however, statin use combined with OS use, but not ICS use, led to significantly lower TB risk.

The results of sensitivity analysis of propensity score--matched cohorts are listed in [Table 5](#jcm-07-00381-t005){ref-type="table"}. TB incidence was 2.31 and 5.15 per 1000 person-years in statin users and nonusers, respectively. Statin users had a 0.37- and 0.47-fold lower TB and pneumonia risks, respectively (95% CI 0.25--0.56 and 0.36--0.61, respectively).

3.1. Sensitivity Analysis {#sec3dot1-jcm-07-00381}
-------------------------

Because most ACOS patients have higher readmission and mortality rates after discharge, we used a time-dependent model and long-term protective effects of statins to follow statin users (8.18 ± 2.76 years) and nonusers (5.99 ± 3.88 years). Long-term use was according to the higher cumulative dose recommended by the strict chronic prescription policy of Taiwan NHI. We further measured ICS and OS use among statin users to examine the effects of statins on TB and pneumonia risk further. [Table 4](#jcm-07-00381-t004){ref-type="table"} presents that the dichotomous effects of statins combined with ICSs or OSs noted in this study are similar to a forest plot.

3.2. Healthy User Bias {#sec3dot2-jcm-07-00381}
----------------------

Considering "healthy user bias" is essential in the retrospective study of the pneumonia and TB outcomes of statin users. This bias is described as a higher awareness of health and a healthier lifestyle among statin users than that among nonusers. Therefore, statin users are potentially more likely to seek preventive health services, such as CXR, PFT, sputum culture, and vaccinations, particularly in the current ACOS cohort. However, measuring lifestyle factors, disease prevention behaviors, and drugs compliance in observational studies is difficult because lifestyle, income, and urbanization are confounded by alcohol-related diseases and sleep and mental disorders. To reduce the impact of the confounding healthy user bias, we measured alcohol-related diseases and sleep and mental disorders through individual insurance as a proxy to adjust for socioeconomic status. Propensity score matching, which included these as baseline variables, further reduced the healthy user bias. Furthermore, the factors associated with latent TB, such as nutrition (e.g., diabetes or hyperlipidemia), immune status, and steroid use, were included in the analysis. These statistical methods enable observational studies to simulate the results of randomized control trials.

3.3. Indication Bias of Statin Use with ICSs or OSs {#sec3dot3-jcm-07-00381}
---------------------------------------------------

The indication bias of statin may also be challenged in this study. In Taiwan, statins and ICSs are not available over the counter; the physicians' decision to provide statin or ICS treatment should not only follow the treatment guidelines for the specific diseases but also the payment regulations by the NHI. If the prescriptions contravene Taiwan lipid guidelines and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, the NHI Administration may not only refuse to pay the medical fee but also punish the physicians with a maximum 100-fold penalty. This is because NHI is a single-payer compulsory insurance coverage policy and the NHI Administration has full authority to control all medical facilities and the concerned health care.

4. Discussion {#sec4-jcm-07-00381}
=============

The most crucial finding of this study was that statin-using ACOS patients had lower TB or pneumonia risk and that concurrent use of statin and ICSs or OSs was also associated a lower TB or pneumonia risk.

In asthma patients, statins can improve outcomes in combination with either ICSs or OSs \[[@B24-jcm-07-00381],[@B25-jcm-07-00381]\]. Emergency rooms and hospitals are the sources of nosocomial infection; therefore, the cohort with superior outcomes and more infrequent visits may exhibit a lower incidence rate for nosocomial pneumonia and TB \[[@B19-jcm-07-00381]\]. Moreover, the antibiotic effects of statins on TB during statin therapy are associated with a decreased active TB risk \[[@B41-jcm-07-00381]\]---an observation supported by the effects of the duration of statin therapy in protecting against TB. A Taiwanese study using the NHIRD also reported that statin use is associated with a lower-than-usual TB risk \[[@B38-jcm-07-00381]\].

According to an US study, ACOS patients can be classified as A (low risk, fewer symptoms, modified Medical Research Council (mMRC) score of 0--1, or COPD assessment test (CAT) score of \<10), B (low risk, more symptoms, mMRC score of \>2, or CAT score of \>10), C (high risk, fewer symptoms, mMRC score of 0--1, or CAT score of \<10), and D (high risk, more symptoms, mMRC score of \>2, or CAT score of \>10). The GOLD classifications characterizes A and B groups by a forced expiratory volume-1 second (FEV1) or forced vital capacity (FVC) of \>50% with exacerbation of \<1 per year and C and D groups by a FEV1 or FVC of \<50% with exacerbation of \>1 per year. Most ACOS patients are categorized in the B and D groups \[[@B34-jcm-07-00381],[@B42-jcm-07-00381]\]. Poor lung function is associated with the development of TB or pneumonia classified in the D group (exacerbation of \>1 per year) \[[@B31-jcm-07-00381]\]. In a study, in COPD patients, statin use may have improved lung function, whereas it may have delayed decline in lung function in asthma patients \[[@B43-jcm-07-00381]\]. These results are similar to those obtained by other studies, where after statin use in ACOS patients, some patients were reclassified from group D into group A (exacerbation of \<1 per year), corresponding to the lowering of TB or pneumonia incidence \[[@B38-jcm-07-00381],[@B42-jcm-07-00381]\]. These results are in accordance with those found in our study.

Improved lung function in COPD and asthma patients may be due to the anti-inflammatory effects of statin use \[[@B44-jcm-07-00381],[@B45-jcm-07-00381],[@B46-jcm-07-00381]\]; moreover, concurrent use of ICSs or OSs with statin can lead to greater lung function improvement in an ACOS cohort \[[@B33-jcm-07-00381]\]. These findings indicate the additive effects of statins and ICSs or OSs \[[@B47-jcm-07-00381],[@B48-jcm-07-00381]\]; the combined use of statins and ICSs or OSs in ACOS patients may have therefore reduce the number of emergency hospital visits and exacerbation events \[[@B24-jcm-07-00381]\] and thus the lower TB and pneumonia incidence, particularly in patients aged \>50 years.

In another study, high long-term ICS or OS dosage was associated with an elevated TB risk in patients with asthma in the COPD cohort, with ICS use leading to the highest risk. Furthermore, exposure to ICSs was not associated with TB risk in the presence of OSs but with an increased TB risk in OS nonusers. The risk of TB among OS users has been well documented; moreover, the negative effects of ICSs have bed reported to be negligible, even at high doses. However, the previous studies have neither involved an ACOS cohort nor adjusted for statin and time dependency in their analyses. A population-based nested case--control study revealed that ICSs were not associated with TB development \[[@B49-jcm-07-00381]\]; however, the benefits of ICSs and OSs may outweigh the risk of pneumonia in statin-using asthma patients \[[@B17-jcm-07-00381],[@B18-jcm-07-00381]\]. ICSs and OSs demonstrated dichotomous effects on the incidence of TB and pneumonia in the ACOS cohort; hence, the effects of concurrent statin and ICS or OS treatment on TB development among patients in the ACOS cohort warrant further research.

The present work demonstrated that statins have beneficial anti-inflammatory and antioxidant effects beyond the reduction of cholesterol levels in TB or pneumonia patients. The accumulation of lipids in macrophages harboring TB is associated with persistent and phenotypic resistance to anti-TB drugs, leading to prolongation of treatment duration \[[@B8-jcm-07-00381]\]. Statins play a role in the attenuation of both TB growth and infection-induced lipid accumulation in macrophages as well as the promotion of phagosomal maturation and autophagy. In line with the other studies, here, statins helped reduce TB development rate. Our study revealed that even with ICS or OS use, statin-using ACOS patients exhibited lower TB and pneumonia incidence. Determination of the correct statin administration dosage, timing, and duration among cohorts requires further confirmation.

By contrast, the reports mention of the statins without relationship or increase of the risk of pneumonia were found \[[@B50-jcm-07-00381]\]. In a study, among 124,695 acute myocardial infarction (AMI) patients, 76,994 (61.9%) has statin prescription; of them, only 19,078 (15.3%) were diagnosed with pneumonia. Using an ordinary least squares method, the statin coefficient indicated that statin prescription was associated with a reduction in pneumonia incidence. However, the instrumental variables indicated that statin use was not associated with the reduction in pneumonia incidence. The study concluded that in AMI patients, the protective effect of statins against pneumonia is most likely the result of nonrandom treatment assignment (i.e., healthy user bias) \[[@B51-jcm-07-00381]\].

In their meta-analysis, Chopra et al. revealed that two prospective studies (Majumdar and Yende et al.) found that statins did not reduce pneumonia-related mortality, but another prospective study (Chalmers et al.) found that they did \[[@B52-jcm-07-00381]\]. Thus, Chopra et al. concluded that although statin use is associated with decreased pneumonia-related mortality, this effect weakens in important subgroups. According to Chalmers et al. statin use in animals reduced endothelial dysfunction and had antithrombotic effects, which improved pneumonia outcomes. Moreover, numerous clinical studies have suggested that statins may have a role in pneumonia prevention or prognosis improvement in hospitalized patients \[[@B53-jcm-07-00381]\]. Only a randomized controlled study can completely explore the link among statins, pneumonia, and pneumonia-related mortality.

Our sensitivity analysis of propensity score--matched cohorts \[[@B54-jcm-07-00381]\] revealed that statins were associated with a lower pneumonia and TB risks. This result may be explained by the different cohort and statistical methods used in the current research. We recommend using the optimal time, dose and duration of the statins may a conjunctive regimen \[[@B55-jcm-07-00381]\] of the antibiotic, anti-TB or OSs/ICs in the ACOS cohort for attenuate the pneumonia sequelae or mortality \[[@B56-jcm-07-00381]\]. These speculations warrant further large-scale research for confirmation.

4.1. Strengths {#sec4dot1-jcm-07-00381}
--------------

In traditional Kaplan--Meier or Cox regression analyses, a typical risk factor measured at baseline correlates with mortality thereafter. During follow-up, however, this may change: either the effect of a fixed baseline risk factor may vary over time, resulting in a weakening or strengthening of associations, or the risk factor itself may vary over time. A strength of the Cox model is its ability to encompass covariates this continually change. The reason for using time-dependent covariates is based on the underlying mechanisms of the Cox model; at the time of each event, the program compares current covariate values of the event subject to the current values of all others at risk at that given time. Time-dependent variables are those that can change in value over the course of the observation period \[[@B57-jcm-07-00381]\]. Variables, such as medicine and the time at which patients receive ICSs or OSs and statins, may vary over time. Although researchers can hold the values of such variables fixed at a certain point in time (e.g., baseline), the changing values may have yielded different or even a more accurate analysis of data simply because we used as much data as possible. In this study, ACOS patients were identified based on COPD and medications used (e.g., ICSs) \[[@B26-jcm-07-00381],[@B36-jcm-07-00381]\]. Moreover, pneumonia, TB, and ACOS diagnoses and follow-up were strongly validated by using other NHIRD-related study \[[@B26-jcm-07-00381],[@B31-jcm-07-00381],[@B37-jcm-07-00381],[@B58-jcm-07-00381]\]. Furthermore, prescription and education policies regarding the use of ICSs or OSs and statins are well established in Taiwan \[[@B59-jcm-07-00381],[@B60-jcm-07-00381]\]. Therefore, this NHIRD study (ACOS cohort and ICS, OS, or statin use) was representative of the real-world situation in Taiwan. We used propensity score matching to validate the sensitivity analysis and avoid selection bias.

4.2. Limitations {#sec4dot2-jcm-07-00381}
----------------

The following major points should be considered: (1) The modeling of a time-dependent covariate involves the selection of a function over time; the form this takes may not be obvious and requires considerable biological insight; (2) The selection of a complex functional form increases the possibility of excessive modeling and overfitting of a data set; (3) Numerous time-dependent covariates closely associated with the units under study are usually generated by that unit (e.g., ICS or OS and statin use) and alter the typical relationship between the hazard and survival functions; (4) time-dependent covariate models, except those under certain circumstances, do not allow the creation of individual predictive time-to-event curves; this is different from the Cox model, which only uses fixed covariate values; (5) Extreme caution must be exercised when modeling time-dependent exposure or treatments, particularly when changes in those variables are related to a participant's health status, such as residential area (urban or rural) and insurance status (insured or uninsured). The opportunities inherent in time-dependent modeling (including the explicit relationship between longitudinal values and event occurrence) must be regarded considering potential biases, strong assumptions necessitated by the lack of other possible explanations, and need to select more complex functional forms for modeling \[[@B40-jcm-07-00381]\]. Biochemical data of statin users and nonusers were unavailable in the NHIRD.

5. Conclusions {#sec5-jcm-07-00381}
==============

In ACOS patients, statin use was associated with lowest TB and pneumonia risks, regardless of age, sex, comorbidities, and ICS or OS use. Pneumonia risk was lower among users of statins combined with ICSs or Oss and TB risk was lower among the users of statins combined with OSs.
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jcm-07-00381-t001_Table 1

###### 

Demographic characteristics and clinical comorbidities.

                                   ACOS   *p*-Value                               
  -------------------------------- ------ ----------- ------ ------ ------ ------ ---------
  Age, years                                                                      \<0.001
  \<50                             1960   17.4        1656   18.0   304    14.8   
  50--64                           3283   29.2        2502   27.2   781    38.1   
  65+                              6013   53.4        5048   54.8   965    47.1   
  Mean ± SD ^a^                    64.1   14.3        64.4   14.8   62.7   11.7   \<0.001
  Gender                                                                          \<0.001
  Women                            5029   44.7        3969   43.1   1060   51.7   
  Men                              6227   55.3        5237   56.9   990    48.3   
  Urbanization level ^§^                                                          0.32
  1 (highest)                      2888   25.7        2367   25.7   521    25.4   
  2                                3116   27.7        2522   27.4   594    29.0   
  3                                1822   16.2        1513   16.4   309    15.1   
  4 (lowest)                       3430   30.5        2804   30.5   626    30.5   
  Monthly income (NTD)                                                            0.001
  \<15,840                         3427   30.5        2872   31.2   555    27.1   
  15,840--25,200                   5379   47.8        4357   47.3   1022   49.9   
  ≥25,200                          2450   21.8        1977   21.5   473    23.1   
  Occupation                                                                      0.005
  White collar                     3996   35.5        3287   35.7   709    34.6   
  Blue collar                      4924   43.8        3967   43.1   957    46.7   
  Others ^‡^                       2336   20.8        1952   21.2   384    18.7   
  Comorbidity                                                                     
  Sleep disorder                   5262   46.8        4127   44.8   1135   55.4   \<0.001
  Diabetes                         2449   21.8        1740   18.9   709    34.6   \<0.001
  Hypertension                     7958   70.7        6219   67.6   1739   84.8   \<0.001
  Hyperlipidemia                   4662   41.4        3026   32.9   1636   79.8   \<0.001
  Mental disorders                 6858   60.9        5443   59.1   1415   69.0   \<0.001
  Alcohol-related illness          1049   9.32        839    9.11   210    10.2   0.02
  Chronic kidney disease           915    8.13        718    7.80   197    9.61   \<0.001
  Tobacco use                      526    4.67        426    4.63   100    4.88   0.63
  Coronary artery disease          5492   48.8        4232   46.0   1260   61.5   \<0.001
  Stroke                           1986   17.6        1591   17.3   395    19.3   0.03
  Acute respiratory failure        1405   12.5        1220   13.3   185    9.02   \<0.001
  Medication                                                                      
  Inhaled corticosteroids (ICSs)   2706   24.0        2148   23.3   558    27.2   \<0.001
  Oral steroids (OSs)              8550   76.0        6876   74.7   1674   81.7   \<0.001

Chi-square test; ^a^ Student's *t* test; Monthly income in New Taiwan Dollar (NT\$; NT\$1 = US\$0.03). ^§^ Urbanization level was categorized into four levels according to the population density of the residential area, with Level 1 and 4 being the most and least urbanized, respectively. ^‡^ Other occupational categories included primarily retired, unemployed, and low-income groups. ACOS: asthma--chronic pulmonary disease overlap syndrome.

jcm-07-00381-t002_Table 2

###### 

Cumulative tuberculosis and pneumonia incidence and hazard ratios of statin users and nonusers.

                                     Statin          
  ---------------------------------- --------------- --------------------------
  Tuberculosis                                       
  Person-years                       55,164          16,771
  Follow-up time (year), Mean ± SD   5.99 ± 3.88     8.18 ± 2.76
  Event, *n*                         384             37
  Rate                               6.96            2.21
  cHR (95% CI)                       1 (Reference)   0.34 (0.25, 0.48) \*\*\*
  aHR (95% CI) ^a^                   1 (Reference)   0.49 (0.34, 0.70) \*\*\*
  Pneumonia                                          
  Person-years                       54,267          16,649
  Follow-up time (year), Mean ± SD   5.89 ± 3.41     8.12 ± 2.76
  Event, *n*                         742             87
  Rate                               13.7            5.23
  cHR (95% CI)                       1 (Reference)   0.40 (0.32, 0.50) \*\*\*
  aHR (95% CI) ^a^                   1 (Reference)   0.52 (0.41, 0.65) \*\*\*

Incidence in per 1000 person-years. ^a^ Data adjusted for age, sex, urbanization level, monthly income, occupation, comorbidities (sleep disorders, diabetes, hypertension, hyperlipidemia, mental disorders, alcohol-related illness, chronic kidney disease, tobacco use, CAD, stroke, and acute respiratory failure), and use of medication (ICSs and OSs). Abbreviations: cHR, crude hazard ratio; aHR, adjusted hazard ratio; ICSs, inhaled corticosteroids; OSs, oral steroids. \*\*\* *p* \< 0.001.

jcm-07-00381-t003_Table 3

###### 

Age- and sex-stratified tuberculosis and pneumonia incidence and hazard ratios.

  --------------------- --------------------- -------------------------- ---------------------- --------------------------
                        **Men**               **Women**                                         
  **Statin**            **Statin**                                                              
  **No (*n* = 5237)**   **Yes (*n* = 990)**   **No (*n* = 3969)**        **Yes (*n* = 1060)**   
  Tuberculosis                                                                                  
  No. of event          282                   26                         102                    11
  Incidence rate        9.30                  3.29                       4.11                   1.24
  cHR (95% CI)          1 (Reference)         0.38 (0.26, 0.57) \*\*\*   1 (Reference)          0.33 (0.18, 0.61) \*\*\*
  aHR (95% CI) ^a^      1 (Reference)         0.53 (0.34, 0.81) \*\*     1 (Reference)          0.41 (0.21, 0.79) \*\*
  Pneumonia                                                                                     
  No. of event          525                   57                         217                    30
  Incidence rate        17.6                  7.27                       8.87                   3.41
  cHR (95% CI)          1 (Reference)         0.43 (0.33, 0.57) \*\*\*   1 (Reference)          0.41 (0.28, 0.60) \*\*\*
  aHR (95% CI) ^a^      1 (Reference)         0.54 (0.41, 0.73) \*\*\*   1 (Reference)          0.47 (0.32, 0.70) \*\*\*
                        **Age \< 50**         **Age ≥ 50**                                      
                        **Statin**            **Statin**                                        
                        **No (*n* = 1656)**   **Yes (*n* = 304)**        **No (*n* = 7550)**    **Yes (*n* = 1746)**
  Tuberculosis                                                                                  
  No. of event          22                    4                          362                    33
  Incidence rate        1.84                  1.50                       8.38                   2.34
  cHR (95% CI)          1 (Reference)         0.85 (0.29, 2.48)          1 (Reference)          0.31 (0.21, 0.44) \*\*\*
  aHR (95% CI) ^a^      1 (Reference)         0.74 (0.22, 2.49)          1 (Reference)          0.45 (0.31, 0.65) \*\*\*
  Pneumonia                                                                                     
  No. of event          33                    2                          709                    85
  Incidence rate        2.78                  0.75                       16.7                   6.08
  cHR (95% CI)          1 (Reference)         0.29 (0.07, 1.21)          1 (Reference)          0.38 (0.30, 0.48) \*\*\*
  aHR (95% CI) ^a^      1 (Reference)         0.20 (0.05, 0.91) \*       1 (Reference)          0.52 (0.41, 0.67) \*\*\*
  --------------------- --------------------- -------------------------- ---------------------- --------------------------

Incidence in per 1000 person-years. ^a^ Data adjusted for age, sex, urbanization level, monthly income, occupation, comorbidities (sleep disorders, diabetes, hypertension, hyperlipidemia, mental disorders, alcohol-related illness, chronic kidney disease, tobacco use, CAD, stroke, and acute respiratory failure), and use of medication (ICSs and OSs). Abbreviations: cHR, crude hazard ratio; aHR, adjusted hazard ratio; ICSs, inhaled corticosteroids; OSs, oral steroids. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001.

jcm-07-00381-t004_Table 4

###### 

ICS and OS use-stratified tuberculosis and pneumonia incidence and hazard ratios.

  --------------------- ---------------------- -------------------------- ---------------------- --------------------------
                        **With ICSs**          **Without ICSs**                                  
  **Statin**            **Statin**                                                               
  **No (*n* = 2148)**   **Yes (*n* = 558)**    **No (*n* = 7058)**        **Yes (*n* = 1492)**   
  Tuberculosis                                                                                   
  No. of event          76                     12                         308                    25
  Incidence rate        5.33                   2.54                       7.53                   2.07
  cHR (95% CI)          1 (Reference)          0.49 (0.26, 0.89) \*       1 (Reference)          0.31 (0.20, 0.46) \*\*\*
  aHR (95% CI) ^a^      1 (Reference)          0.60 (0.31, 1.16)          1 (Reference)          0.44 (0.29, 0.67) \*\*\*
  Pneumonia                                                                                      
  No. of event          151                    26                         591                    61
  Incidence rate        10.8                   5.56                       14.7                   5.09
  cHR (95% CI)          1 (Reference)          0.52 (0.34, 0.78) \*\*     1 (Reference)          0.37 (0.29, 0.48) \*\*\*
  aHR (95% CI) ^a^      1 (Reference)          0.61 (0.39, 0.95) \*       1 (Reference)          0.48 (0.36, 0.63) \*\*\*
                        **With OSs**           **Without Oss**                                   
  **Statin**            **Statin**                                                               
  **No (*n* = 6876)**   **Yes (*n* = 1674)**   **No (*n* = 2330)**        **Yes (*n* = 376)**    
  Tuberculosis                                                                                   
  No. of event          237                    34                         147                    3
  Incidence rate        5.61                   2.46                       11.4                   1.02
  cHR (95% CI)          1 (Reference)          0.46 (0.32, 0.66) \*\*\*   1 (Reference)          0.10 (0.03, 0.32) \*\*\*
  aHR (95% CI) ^a^      1 (Reference)          0.58 (0.40, 0.85) \*\*     1 (Reference)          0.16 (0.05, 0.53) \*\*
  Pneumonia                                                                                      
  No. of event          534                    79                         208                    8
  Incidence rate        12.9                   5.76                       16.1                   2.72
  cHR (95% CI)          1 (Reference)          0.46 (0.36, 0.58) \*\*\*   1 (Reference)          0.19 (0.09, 0.38) \*\*\*
  aHR (95% CI) ^a^      1 (Reference)          0.57 (0.45, 0.74) \*\*\*   1 (Reference)          0.26 (0.12, 0.53) \*\*\*
  --------------------- ---------------------- -------------------------- ---------------------- --------------------------

Incidence in per 1000 person-years. ^a^ Data adjusted for age, sex, urbanization level, monthly income, occupation, comorbidities (sleep disorders, diabetes, hypertension, hyperlipidemia, mental disorders, alcohol-related illness, chronic kidney disease, tobacco use, CAD, stroke, and acute respiratory failure), and use of medication (ICSs and OSs). Abbreviations: cHR, crude hazard ratio; aHR, adjusted hazard ratio; ICSs, inhaled corticosteroids; OSs, oral steroids. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001.

jcm-07-00381-t005_Table 5

###### 

Overall tuberculosis and pneumonia incidence and hazard ratios in statin users vs. propensity score--matched statin nonusers.

                                     Statin          
  ---------------------------------- --------------- --------------------------
  Tuberculosis                                       
  Person-years                       14,570          16,040
  Follow-up time (year), Mean ± SD   7.34 ± 3.25     8.08 ± 2.75
  Event, *n*                         75              37
  Rate                               5.15            2.31
  cHR (95% CI)                       1 (Reference)   0.38 (0.26, 0.57) \*\*\*
  aHR (95% CI) ^a^                   1 (Reference)   0.37 (0.25, 0.56) \*\*\*
  Pneumonia                                          
  Person-years                       14,308          15,924
  Follow-up time (year), Mean ± SD   7.21 ± 3.32     8.03 ± 2.75
  Event, *n*                         150             86
  Rate                               10.5            5.40
  cHR (95% CI)                       1 (Reference)   0.49 (0.38, 0.64) \*\*\*
  aHR (95% CI) ^a^                   1 (Reference)   0.47 (0.36, 0.61) \*\*\*

Incidence in per 1000 person-years. ^a^ Data adjusted for age, sex, urbanization level, monthly income, occupation, comorbidities (sleep disorders, diabetes, hypertension, hyperlipidemia, mental disorders, alcohol-related illness, chronic kidney disease, tobacco use, CAD, stroke, and acute respiratory failure), and use of medication (ICSs and OSs). Abbreviations: cHR, crude hazard ratio; aHR, adjusted hazard ratio; ICSs, inhaled corticosteroids; OSs, oral steroids. \*\*\* *p* \< 0.001.
